- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...

WASHINGTON — North Carolina Governor Josh Stein announced Monday that Genentech will invest $700 million to construct a new manufacturing plant in Holly Springs, creating 400 jobs. "World-class ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...

The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...

The FDA approved the biotechnology company Genentech’s Xofluza drug to treat children aged 5-12 with influenza. Xofluza is the first single-dose influenza drug approved by the FDA to treat children in ...

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...

Over the past day, Genentech has been making a concerted bid to expand its partnered portfolio into the hottest R&D areas. Only hours after the Roche unit signed a radiopharmaceutical-focused pact ...

Biotechnology company Genentech is expanding its local manufacturing capabilities with a $450 million investment in its Oceanside campus. Genentech was founded in 1976 and has been considered a ...

Focusing on the 'sandwich generation' - adults caring for ageing parents while raising children - this impactful film from ...